BASEL, Switzerland, Nov. 28 /CNW/ - With the public interest in Tamiflu
continuing, Roche keeps interested physicians and governments updated on
current developments and today, informs on the topic of resistance. There have
been no new cases of resistance seen in patients infected with H5N1 virus
('bird flu') since March 2005 and scientific data does not substantiate
increased resistance to Tamiflu (oseltamivir). Roche is providing this update
on the topic so that physicians and governments can be confident that Tamiflu
can continue to be effectively used in the treatment and prophylaxis of
seasonal and H5N1 influenza.
